1 2

Obagi

Obagi-C RX Exfoliating Day

Obagi-C RX Exfoliating Day

$ 80.00
$ 80.00
Sale Sold out
Shipping calculated at checkout.

A smooth, lightweight moisturizer that hydrates and gently exfoliates with glycolic acid to reveal a brighter, healthier-looking complexion.*

Key Ingredients:
Glycolic Acid, Ascorbyl Glucoside, Hyaluronic Acid, Vitamin E, Glycerin

*Sunburn Alert: This product contains an alpha hydroxy acid (AHA) that may increase your skin's sensitivity to the sun and particularly the possibility of sunburn. Use a sunscreen, wear protective clothing, and limit sun exposure while using this product and for a week afterwards.

Early Intervention for Signs of Skin Damage

With Obagi-C Rx, you’re on your way to softer, smoother, radiant, and more even-looking skin. The Obagi-C Rx System offers 4% hydroquinone to reduce hyperpigmentation, and other key ingredients that help address the signs of skin aging to maintain younger-looking skin.

Obagi-C Rx System products are ideal if you have:

  • Hyperpigmentation, sun damage, and age spots
  • Uneven skin tone
  • Rough skin
  • The appearance fine lines and wrinkles
  • Dry, normal, or oily skin

Clinically Supported Ingredients

Prescription 4% hydroquinone

  • Improves hyperpigmentation (brown spots)
  • Provides a lighter, more even-toned complexion

Other key ingredients that address the signs of skin aging

  • An exfoliator helps support skin turnover through gentle exfoliation
  • 10% L-ascorbic acid (Vitamin C) helps defend against free radicals
  • A broad spectrum sunscreen helps protect against harmful UVA and UVB rays

Deep Skin Absorption

When the Obagi-C Rx C-Clarifying Serum with C-Balancing Toner were compared to SkinCeuticals Phloretin CF®, another leading Vitamin C product, more Vitamin C remained in the skin at 24 hours.1,*

*Based on in vitro studies. Clinical significance has not been established.

Reference: 1. Lehman PA, Investigator, Cetero Research. Evaluation of the percutaneous absorption of 14C-ascorbic acid, in vitro, using the Franz human skin finite dose model (protocol R09-0715). Data on file. 

View full details